Anti-ErbB2 antibodies

• US 20080112957A1
• Filed: 10/31/2007
• Published: 05/15/2008
• Est. Priority Date: 10/18/1996
• Status: Abandoned Application

• Current Assignee: Genentech, Inc. (Roche Holding AG), Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Genentech, Inc. (Roche Holding AG), Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Uhr, Jonathan, Scheuermann, Richard, Fendly, Brian, Phillips, Gail
• Application Number:
  US11/981,602
• Publication Number:
  US 20080112957A1
• Time in Patent Office: Days
• US Class Current: 424/139.1
• CPC Class Codes: A61J 1/00 Containers specially adapted for medical or pharmaceutical purposes capsules or the like for oral use A61J3/07; specially adapted for surgical or diagnostic appliances or instruments A61B50/30; containers for radioactive substances G21F5/00
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: B65D 25/205 Means for the attachment of labels, cards, coupons or the like; cards or coupons for the other types of rigid or semi-rigid containers B65D25/36 takes precedence
• CPC Class Codes: C07K 16/2863 against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 16/3015 Breast
• CPC Class Codes: C07K 16/3069 Reproductive system, e.g. ovaria, uterus, testes, prostate
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 17/00 Carrier-bound or immobilised peptides carrier-bound or immobilised enzymes C12N11/00; Preparation thereof
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/567 Framework region [FR]
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 2333/71 for growth factors; for growth regulators
• CPC Class Codes: G01N 2333/912 transferring phosphorus containing groups, e.g. kinases (2.7)
• CPC Class Codes: G01N 33/573 : for enzymes or isoenzymes
• CPC Class Codes: G01N 33/5748 : involving oncogenic proteins

Abstract

Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.

Claims

1-41. -41. (canceled)

42. A composition comprising a first isolated antibody that binds Domain 1 (SEQ ID NO:

1) of ErbB2 and thereby induces cell death in cells overexpressing ErbB2.

43. The composition of claim 42, wherein said antibody binds epitope 7C2/7F3 (SEQ ID NO:

2) of ErbB2.

44. The composition of claim 42, wherein said antibody comprising CDRs of antibody 7C2 or 7F3.

45. The composition of claim 42, wherein said antibody induces apoptosis in said cells.

46. The composition of claim 42, further comprising an isolated second antibody that binds ErbB2 at a different domain than Domain 1 and inhibits growth of cells overexpressing ErbB2.

47. The composition of claim 46, wherein said first antibody comprises CDRs of antibody 7C2 or 7F3.

48. The composition of claim 46, wherein said second antibody comprises CDRs of antibody 4D5.

49. The composition of claim 46, wherein said first antibody comprises CDRs of antibody 7C2 or 7F3 and said second antibody comprises CDRs of antibody 4D5.

50. An isolated nucleic acid sequence encoding antibody that binds Domain 1 (SEQ ID NO:

1) of ErbB2 and thereby induces cell death in cells overexpressing ErbB2.

51. The nucleic acid sequence of claim 50, encoding an antibody that binds epitope 7C2/7F3 (SEQ ID NO:

2) of ErbB2.

52. The nucleic acid sequence of claim 50, encoding an antibody comprising CDRs of antibody 7C2 or 7F3.

53. The nucleic acid sequence of claim 52, further composing a nucleic acid sequence encoding a second antibody comprising CDRs of antibody 4D5.

54. A host cell comprising a nucleic acid sequence encoding an antibody comprising CDRs of antibody 7C2 or 7F3.

55. The host cell of claim 54, further comprising a nucleic acid sequence encoding a second antibody comprising CDRs of antibody 4D5.

56. The host cell of claim 54, wherein the host cell is a hybridoma cell line.

57. A kit comprising an antibody that binds Domain 1 (SEQ ID NO:

1) of ErbB2 and thereby induces cell death in cells overexpressing ErbB2 and a second antibody that binds ErbB2 at a different domain than Domain 1 and inhibits growth of cells overexpressing ErbB2, adapted for simultaneous or sequential administration.

58. A method for inducing cell death in cell that overexpresses ErbB2, comprising exposing a cell that overexpresses ErbB2 to an isolated antibody that binds Domain 1 (SEQ ID NO:

1) of ErbB2, thereby inducing apoptosis in said cells.

59. The method of claim 58, wherein said antibody binds epitope 7C2/7F3 (SEQ ID NO:

2) of ErbB2.

60. The method of claim 58, wherein said antibody comprises CDRs of antibody 7C2 or 7F3.

61. The method of claim 58, further comprising exposing said cell to radiation.

62. The method of claim 58, further comprising exposing said cell to a chemotherapeutic agent.

63. The method of claim 58, further comprising exposing said cell to a second antibody that binds ErbB2 at a different domain than Domain 1 and inhibits growth of cells overexpressing ErbB2.

64. The method of claim 63, wherein said second antibody comprises CDRs of antibody 4D5.

65. The method of claim 63, wherein said first antibody comprises CDRs of antibody 7C2 or 7F3 and said second antibody comprises CDRs of antibody 4D5.

66. The method of claim 63, wherein said cell is exposed to said antibody that binds Domain 1 prior to exposure of the cell to said second antibody.